Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Jan-Dec:11:23247096231191874.
doi: 10.1177/23247096231191874.

Mifepristone-Induced Hypothyroidism

Niketa Kalara  1 , Alex Manzano  1
Affiliations
Case Reports

Mifepristone-Induced Hypothyroidism

Niketa Kalara et al. J Investig Med High Impact Case Rep. 2023 Jan-Dec.

Abstract

Medications are known to affect the thyroid physiology and are a known cause of hypothyroidism. There is an ever-growing list of medications that affect the thyroid by 1 or more mechanisms. Mifepristone is presently used for the treatment of mild autonomous cortisol secretion (MACS). Hypothyroidism is not a known side effect of this medication. We present a 71-year-old woman with newly diagnosed impaired fasting glucose, dyslipidemia, and osteopenia presenting with a 3-year history of unintentional 15-pound weight gain (despite exercise and a good diet) and increased anxiety. Her physical examination was pertinent for mild lower extremity edema, easy bruising, and skin thinning. Workup revealed adrenocorticotropic hormone (ACTH)-independent MACS from bilateral micronodular hyperplasia of the adrenals. Since she was not a surgical candidate, medical management with mifepristone was chosen. While on mifepristone, she complained of excessive fatigue, a workup done revealed new-onset hypothyroidism. Given her symptoms and bloodwork, she was started on levothyroxine. After stopping mifepristone, she was biochemically and clinically euthyroid and was eventually off levothyroxine. The mechanism by which mifepristone induces hypothyroidism is unknown. Except for a multicenter case series suggesting that mifepristone increases thyroid hormone requirements in patients with central hypothyroidism, to the best of our knowledge, the literature on euthyroid patients developing hypothyroidism secondary to mifepristone is scarce. In conclusion, while the hypothyroidism seems reversible our case highlights the importance of getting baseline thyroid function tests (TFTs) and repeating them while on the medication. Treatment of hypothyroidism is based on symptoms and bloodwork.

Keywords: MACS; drug-induced hypothyroidism; hypercortisolism; mifepristone; thyroid.

PubMed Disclaimer

Conflict of interest statement

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Graph 1.
Graph 1.
Graphical representation of TFT in relation to mifepristone. Abbreviation: TFT, thyroid function test.
See this image and copyright information in PMC

References

    1. Rizzo LFL, Mana DL, Serra HA. Drug-induced hypothyroidism. Medicina. 2017;77:394-404. - PubMed
    1. Brown DR, East HE, Eilerman BS, et al.. Clinical management of patients with Cushing syndrome treated with mifepristone: consensus recommendations. Clin Diabetes Endocrinol. 2020;6:18. - PMC - PubMed
    1. Chiodini I. Clinical review: diagnosis and treatment of subclinical hypercortisolism. J Clin Endocrinol Metab. 2011; 96(5):1223-1236. - PubMed
    1. Fleseriu M, Biller BM, Findling JW, et al.. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing’s syndrome. J Clin Endocrinol Metab. 2012;97(6):2039-2049. - PubMed
    1. Reincke M. Subclinical Cushing’s syndrome. Endocrinol Metab Clin North Am. 2000;29:43-56. - PubMed